Bioventus launches Durolane knee treatment in Taiwan

Bioventus said today it entered the Taiwanese patient care market with the launch of its Durolane single-injection joint-fluid osteoarthritis treatment.

The treatment is based around the NASHA process which produces stabilized hyaluronic acid which provides lubrication and cushioning in a normal joint.

“The combination of a leading OA solution like Durolane and Taiwan’s robust economy gives Bioventus a terrific opportunity to establish itself and grow in this market. Orthobiologic solutions from Bioventus are now available in 6 countries in the Asia Pacific region and we plan to build on this as we continue our international expansion,” CEO Tony Bihl said in a press release.

Durolane has been cleared with an indication for the treatment of mild to moderate osteoarthritis of the knee, the Durham, N.C.-based company said.

“In Taiwan, Bioventus will be working with Eulogiums, a sales and marketing leader with more than 20 years of experience in orthopaedics. The company’s market coverage, relationships with key opinion leaders, along with its keen understanding of markets and trends made it the natural choice to help us introduce Durolane to patients with knee OA,” international managing director Isabelle Levy-Unger said in prepared remarks.

“We believe that only knee OA products with superior quality can withstand in the competitive market in Taiwan and we have confidence that Durolane is the one,” Eulogiums CEO Kenny Liu said in a prepared statement.

Last month, Bioventus said it acquired BioStructures, a developer of absorbable bone grafts, for an undisclosed amount.

The deal for Newport Beach, Calif.-based BioStructures covers its entire line of products, including the Interface bioactive bonegraft and Signafuse bioactive bonegraft putty, plus its R&D pipeline; BioStructures employees will be given offers at Bioventus.

Created in a 2012 spinout worth $367 million from Smith & Nephew (FTSE:SN, NYSE:SNN), Durham, N.C.-based Bioventus sells an ultrasound system to promote bone healing and injections to alleviate knee osteoarthritis. Last fall, Bioventus acquired the OsteoAMP product line from Advanced Biologics for an undisclosed amount.

The post Bioventus launches Durolane knee treatment in Taiwan appeared first on MassDevice.

from MassDevice http://ift.tt/22HqKWh